Trials / Approved For Marketing
Approved For MarketingNCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Expanded Access Program for Pirtobrutinib for Previously Treated B-Cell Cancers
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Loxo Oncology, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an expanded access program for eligible participants with a previously treated B-cell cancer who are ineligible for an ongoing pirtobrutinib clinical trial. The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Lymphocytic, Small
- Lymphoma, Mantle-Cell
- Waldenstrom Macroglobulinemia
- Ritcher's Transformation, Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirtobrutinib | Administered orally. |
Timeline
- First posted
- 2021-12-29
- Last updated
- 2024-12-18
Source: ClinicalTrials.gov record NCT05172700. Inclusion in this directory is not an endorsement.